Dan S. Johnston Sells 8,850 Shares of Omnicell Inc. (OMCL) Stock
Omnicell Inc. (NASDAQ:OMCL) EVP Dan S. Johnston sold 8,850 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $33.65, for a total value of $297,802.50. Following the transaction, the executive vice president now owns 58,877 shares of the company’s stock, valued at approximately $1,981,211.05. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Omnicell Inc. (NASDAQ:OMCL) opened at 34.90 on Tuesday. The stock’s 50 day moving average price is $34.46 and its 200-day moving average price is $35.22. The company has a market cap of $1.27 billion, a P/E ratio of 160.09 and a beta of 0.65. Omnicell Inc. has a 52-week low of $25.06 and a 52-week high of $40.50.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, October 27th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.41 by $0.01. Omnicell had a net margin of 1.24% and a return on equity of 10.74%. The firm earned $179.40 million during the quarter, compared to analyst estimates of $179.75 million. During the same period in the previous year, the company posted $0.36 EPS. Omnicell’s revenue for the quarter was up 43.3% compared to the same quarter last year. Equities analysts expect that Omnicell Inc. will post $1.55 EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. Sheets Smith Wealth Management purchased a new position in Omnicell during the third quarter valued at approximately $526,000. Price T Rowe Associates Inc. MD increased its position in Omnicell by 12.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 472,510 shares of the company’s stock valued at $18,097,000 after buying an additional 53,430 shares during the last quarter. Martin & Co. Inc. TN increased its position in Omnicell by 1.7% in the third quarter. Martin & Co. Inc. TN now owns 35,095 shares of the company’s stock valued at $1,344,000 after buying an additional 600 shares during the last quarter. D. E. Shaw & Co. Inc. increased its position in Omnicell by 25.6% in the third quarter. D. E. Shaw & Co. Inc. now owns 28,037 shares of the company’s stock valued at $1,074,000 after buying an additional 5,718 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in Omnicell during the third quarter valued at approximately $916,000. 94.56% of the stock is currently owned by institutional investors.
OMCL has been the subject of several research analyst reports. Sidoti downgraded Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price objective for the company. in a research report on Thursday, September 8th. Oppenheimer Holdings Inc. set a $46.00 price objective on Omnicell and gave the company a “buy” rating in a research report on Thursday, October 27th. Zacks Investment Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. FBR & Co lifted their price objective on Omnicell from $40.00 to $41.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. Finally, TheStreet downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $39.43.
Omnicell Company Profile
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.